In a phase 2, randomized, double-blind, placebo-controlled, and crossover interventional study conducted at Changhua Christian Hospital in Taiwan, an administration of undeclared composition of TCM formulation for 36 weeks has been suggested to modulate insulin-like growth factor-1 (IGF-1) signaling systems among the young and elderly subjects diagnosed with SCA3. The gene discussed is IGF1; the disease is Spinocerebellar ataxia type 3.